Major Depressive Disorder (MDD) - Market Insights, Epidemiology and Market Forecast to 2027 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 30, 2018--The “Major Depressive Disorder (MDD) - Market Insights, Epidemiology and Market Forecast-2027” report has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Major Depressive Disorder (MDD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Major Depressive Disorder (MDD) from 2016 to 2027 segmented by seven major markets.
The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Disease Understanding & Treatment Algorithm
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Also called Major Depressive Disorder or clinical depression, it affects how patients feel, think and behave and can lead to a variety of emotional and physical problems.
The exact cause of Major Depressive Disorder (MDD) isn’t known. However, there are several factors that can increase the risk of developing the condition. A combination of genes and stress can affect brain chemistry and reduce the ability to maintain mood stability. Changes in the balance of hormones might also contribute to the development of Major Depressive Disorder (MDD).
Symptoms of Major Depressive Disorder (MDD) may include - Feelings of sadness, tearfulness, hopelessness, Sleep disturbances, including insomnia or sleeping too much, Anxiety, agitation or restlessness etc.
The report gives the thorough understanding of the Major Depressive Disorder (MDD) by including details such as disease definition, clinical manifestations, risk factors, pathogenesis, and diagnostic trends, prognosis and prevention. It also provides treatment algorithms and treatment guidelines for Major Depressive Disorder (MDD) in the US, Europe, and Japan.
As per Anxiety and Depression Association of America (ADAA), the leading cause of MDD disability in the U.S. for ages 15 to 44.3. MDD affects about 6.7% of the U.S. population age 18 and older in a given year. While Major Depressive Disorder can develop at any age, the median age at onset is 32.5 years old. More prevalent in women than in men.
According to National Institute of Mental Health (NIMH), the prevalence of adults with a major depressive episode was highest among individuals aged 18-25 (10.9%). Major depression is one of the most common mental disorders in the United States. In 2016, an estimated 10.3 million U.S. adults aged 18 or older had at least one major depressive episode with severe impairment. This number represented 4.3% of all U.S. adults. The prevalence of major depressive episode was higher among adult females (8.5%) compared to males (4.8%). The prevalence of adults with a major depressive episode was highest among individuals aged 18-25 (10.9%).
This research estimates that the prevalent population of Major Depressive Disorder (MDD) will significantly change during the study period [2016-2027].
Currently treatment of Major Depressive Disorder (MDD) include - Antidepressant medications (Selective serotonin reuptake inhibitors (SSRIs), Serotonin-norepinephrine reuptake inhibitors (SNRIs), Monoamine oxidase inhibitors (MAOIs), Tricyclic antidepressants and atypical antidepressants).
Additionally, there are some FDA approved therapies for the treatment of Major Depressive Disorder (MDD) which include-Aripiprazole (BristolMyers Squibb), Aplenzin (Valeant Pharmaceuticals), Emsam (Somerset pharmaceuticals).
Key players such as Fabre-Kramer Pharmaceuticals, Sage Therapeutics and many others are involved in developing therapies for Major Depressive Disorder (MDD). Expected launch of emerging therapies such as Travivo (Fabre-Kramer Pharmaceuticals), SAGE-217 (Sage Therapeutics) and some other are expected to change the treatment landscape of Major Depressive Disorder (MDD) in upcoming years.
Companies FeaturedFabre-Kramer Pharmaceuticals Sage Therapeutics
Key Topics Covered
1. Report Introduction
2. Major Depressive Disorder (MDD) Market Overview at a Glance
3. Disease Background and Overview: Major Depressive Disorder (MDD)
4. Epidemiology and Patient Population
5. Major Depressive Disorder (MDD): Country-Wise Epidemiology
6. Treatments & Medical Practices
7. Marketed Drug
8. Emerging Therapies
9. Major Depressive Disorder (MDD) Market Size
10. 7MM: Country-Wise Market Analysis
11. Market Drivers
12. Market Barriers
13. Report Methodology
For more information about this report visit https://www.researchandmarkets.com/research/ldbx8c/major_depressive?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005266/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Mental Disorders Drugs
INDUSTRY KEYWORD: HEALTH MENTAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 11/30/2018 09:39 AM/DISC: 11/30/2018 09:39 AM